Payment overview · 2025
General Payments
$129.77
7 reported records · 5 companies
Healthcare provider profile · identity verified
Gabriel M Naventi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEE, MA · NPI 1659518462
Verified facts
What the public records show
CMS Open Payments records show Gabriel M Naventi, MD received $129.77 in general payments during 2025 across 7 reported records.
Indivior Inc. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 526 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $36.58 | 28.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.67 | 25.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.65 | 18.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.00 | 16.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.87 | 11.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $129.77 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $36.58 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.67 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.67 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 526 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
151 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
79 | 78 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
526 | 62 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 819 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 818 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 644 | 132 |
| Eliquis | Apixaban | 526 | 62 |
| Lisinopril | Lisinopril | 503 | 115 |
| Gabapentin | Gabapentin | 499 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 489 | 111 |
| Omeprazole | Omeprazole | 457 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 361 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 318 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 311 | 65 |
| Furosemide | Furosemide | 286 | 74 |
| Sertraline Hcl | Sertraline Hcl | 283 | 51 |
| Trazodone Hcl | Trazodone Hcl | 283 | 68 |
| Losartan Potassium | Losartan Potassium | 270 | 63 |
| Simvastatin | Simvastatin | 215 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 208 | 36 |
| Mirtazapine | Mirtazapine | 196 | 30 |
| Torsemide | Torsemide | 192 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 36 |
| Donepezil Hcl | Donepezil Hcl | 181 | 28 |
| Metformin Hcl | Metformin Hcl | 181 | 41 |
| Lorazepam | Lorazepam | 180 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 35 |
| Prednisone | Prednisone | 167 | 90 |
| Allopurinol | Allopurinol | 160 | 42 |
| Finasteride | Finasteride | 160 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 159 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 46 |
| Potassium Chloride | Potassium Chloride | 159 | 37 |
| Spironolactone | Spironolactone | 155 | 28 |
| Tramadol Hcl | Tramadol Hcl | 152 | 51 |
| Jardiance | Empagliflozin | 151 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 131 | 23 |
| Warfarin Sodium | Warfarin Sodium | 130 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 31 |
| Divalproex Sodium | Divalproex Sodium | 118 | 21 |
| Olanzapine | Olanzapine | 109 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 106 | 23 |
| Pregabalin | Pregabalin | 101 | 30 |
| Famotidine | Famotidine | 94 | 25 |
| Meloxicam | Meloxicam | 89 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 16 |
| Farxiga | Dapagliflozin Propanediol | 88 | 12 |
| Topiramate | Topiramate | 88 | 12 |
| Metformin Hcl Er | Metformin Hcl | 85 | 26 |
| Xarelto | Rivaroxaban | 85 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 33 |
| Clonazepam | Clonazepam | 81 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 24 |
| Bupropion Xl | Bupropion Hcl | 80 | 18 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 79 | 78 |
| Risperidone | Risperidone | 78 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 75 | 75 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 74 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 12 |
| Levetiracetam | Levetiracetam | 74 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 44 |
| Alendronate Sodium | Alendronate Sodium | 70 | 15 |
| Atenolol | Atenolol | 70 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 18 |
| Memantine Hcl | Memantine Hcl | 66 | suppressed |
| Glimepiride | Glimepiride | 64 | 14 |
| Myrbetriq | Mirabegron | 63 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 11 |
| Trulicity | Dulaglutide | 63 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 50 |
| Glipizide Er | Glipizide | 57 | 12 |
| Valsartan | Valsartan | 55 | 16 |
| Labetalol Hcl | Labetalol Hcl | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 38 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 12 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 52 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | suppressed |
| Lovastatin | Lovastatin | 52 | suppressed |
| Alprazolam | Alprazolam | 51 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 17 |
| Carvedilol | Carvedilol | 48 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 45 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 28 |
| Divalproex Sodium Er | Divalproex Sodium | 42 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 11 |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Venlafaxine Hcl | Venlafaxine Hcl | 37 | suppressed |
| Carbamazepine Er | Carbamazepine | 35 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Testosterone | Testosterone | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | 12 |
| Lactulose | Lactulose | 32 | suppressed |
| Nystop | Nystatin | 32 | 20 |
| Ozempic | Semaglutide | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | 11 |
| Cilostazol | Cilostazol | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Restasis | Cyclosporine | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 25 |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 26 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 26 | 12 |
| Mupirocin | Mupirocin | 26 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | 11 |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 17 |
| Azithromycin | Azithromycin | 20 | 20 |
| Folic Acid | Folic Acid | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 13 |
| Nystatin | Nystatin | 19 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | 13 |
| Glipizide | Glipizide | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 15 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 14 | suppressed |
| Budesonide Ec | Budesonide | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Klonopin | Clonazepam | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Rhopressa | Netarsudil Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129.77 · 7 records | Indivior Inc. | AREXVY, ELIQUIS, KISUNLA, NURTEC ODT, OTEZLA, REPATHA, SHINGRIX, SUBLOCADE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error